Peak 2019 memorabilia
Release time:
2020-07-15
January
On January 28, the Group held a business analysis meeting to review and summarize the business situation in 2018 and deploy the key work in 2019.
On January 29, the Group held the 2018 Annual Summary and Recognition Conference.
March
Peak Guizhou Huangping Cement Project Held Commencement Ceremony.
Jianfeng Pharmaceutical Preparation The original Jinxi Pharmaceutical Factory and Qiubin Pharmaceutical Factory were merged into Jianfeng Pharmaceutical Factory, and unified management was implemented.
The cement produced by Daye Peak Cement Company successfully won the bid for the national key project Huang (Mei) Huang (Zhou) Railway Project.
April
On April 17, Jianfeng Group and Agricultural Bank of China Zhejiang Branch held a signing ceremony for special poverty alleviation counterpart loans in Huangping County, Guizhou Province. Agricultural Bank of Zhejiang Province will provide special loans for Jianfeng Guizhou Huangping Cement Project.
Daye Peak Manufacturing Department won the honorary title of "Worker Pioneer" in Huangshi City.
May
The company implemented the "Safety Production Risk Assessment Management System".
Peak development achievements were included in the book "Glory of the New Era" jointly compiled by Zhejiang Industrial Economic Federation, Zhejiang Enterprise Federation, and Zhejiang Entrepreneurs Association.
Peak Pharmaceutical's new product Berunning (Olopatadine Hydrochloride Eye Drops) held a launch conference in Shanghai.
Du Zihong, the first chairman of the group company, died of illness.
June
Spike Health Cranberry Extract won the Plant Extract Technology Innovation Award from China Chamber of Commerce for Import and Export of Medicines and Health Products.
Industrial Building Materials Industry Association was established in Pu'er City, and Yunnan Jianfeng was elected as the first executive chairman unit.
On June 29, the Party Committee of the Group Company and the Party Branch of Jiangbei Sub-branch of China Merchants Bank, the co-construction unit, jointly organized party members and cadres to go to the old revolutionary base of Yinkeng Village, Shafan Township, Jinhua, to cherish the memory of the revolutionary ancestors and review the history of the national party. The theme education of "Do not forget your initiative mind, Remember Mission" of Jianfeng Group Party Committee kicked off.
Peak Pharmaceutical ranked 74th in the "Top 100 Chinese Pharmaceutical Enterprises" released by the National Pharmacy Week and China Pharmaceutical Innovation and Development Conference.
July
The selection of the third batch of reserve talents of the group company was completed, and 30 young talents were selected into the company's reserve talent pool.
The company started the standardization construction work.
August
Peak International Trading Company Becomes Zhengzhou Commodity Exchange Cotton Yarn Delivery Warehouse.
Spike International Trading Company was selected as a 2019 Zhejiang Province Car-Free Carrier Logistics Pilot Enterprise.
Shanghai North Carolina "quality improvement and industrialization optimization of erlotinib hydrochloride and its advanced intermediates" technical achievements won the Shanghai Excellent Invention Bronze Award.
September
On the morning of September 16, the foundation of the internationalization project of 2 billion solid preparations per year in Jinxi Production Base of Jianfeng Pharmaceutical Co., Ltd. was laid.
Before the National Day, the Central Committee of the Communist Party of China, the State Council, and the Central Military Commission jointly issued the "Celebrating the 70th Anniversary of the Founding of the the People's Republic of China" commemorative medal. 19 veteran comrades of the peak won this honor.
October
Peak invested 1 million yuan to set up a "Hypertension Community Prevention and Control Training Fund" to carry out multi-level and wide-coverage standardized diagnosis and treatment training for primary hypertension nationwide.
November
Peak Guizhou Huangping Project (formerly Guizhou Huangping Valley Longmingchuan Cement Co., Ltd.) was officially renamed "Guizhou Huangping Peak Cement Co., Ltd".
On November 8, the group party committee held the eighth party member congress to elect a new party committee and discipline inspection committee.
On November 15, Daye Peak held a "Peak Cup" photography competition. Photographers from Huangshi City walked into the enterprise and used the lens to freeze the construction achievements of Daye Peak's "Green Factory" and "Garden Factory" and the spiritual outlook of employees.
On November 20, the principal and interest payment of the 2013 corporate bonds (Phase II) was successfully completed. So far, all the corporate bonds approved for issuance by the company in 2013 have been paid.
On November 28, the "Colorful Yunnan" National Fitness Games and the 3rd "Peak Cup" Basketball Invitational Tournament hosted by Yunnan Peak Cement Company opened in Simao Stadium.
Yunnan Jianfeng Cement Company was awarded the title of "Yunnan Provincial Growth Small and Medium-sized Enterprises" by the Yunnan Provincial Department of Industry and Information Technology.
December
In the 10th New Medical Observer Forum and the National Medical Elite Club Annual Meeting held in Chongqing on December 3, Jianfeng Pharmaceutical won the "2019 Most Brand Value Pharmaceutical Industry Enterprise" award, and the product Berunning (Olopatadine Hydrochloride Eye Drops) won the "2019 Most Concerned Consistency Evaluation Variety Award".
On December 13, the Shanghai Securities News held the "High-quality Development Forum of 2019 listed companies" and the "Golden quality" award ceremony. Jianfeng Group won the "Golden quality" sustained growth Award of listed companies on the Shanghai Stock Exchange. Jinhua is the only listed company in Jinhua to win this award.
Anhui Jianfeng Beika Pharmaceutical and Anhui Zhongwang Pharmaceutical Phase II Project laid the foundation.
Jianfeng Group was listed in the "Top 100 Building Materials Enterprises in China in 2019".
Jianfeng Group passed the second stage acceptance of the "three" cultivation pilot enterprises organized by the relevant competent departments of Zhejiang Province, and the related work of the "three" project was successfully completed.
Peak put high-speed rail title advertisement through bidding. On January 2, 2020, the "Jianfeng Group" high-speed railway between Shanghai and Kunming was launched at Kunming South Railway Station.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31